Aarti Pharmalabs (NSE:AARTIPHARM) Notes Receivable: ₹0 Mil (As of Mar. 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
50 GF Score
Price ₹701.70
GF Value ₹641.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Notes Receivable?

Aarti Pharmalabs NSE:AARTIPHARM +3.18% 50 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 50/100 and a GF Value™ of ₹641.17 (Fairly Valued). The stock has 3 warning signs investors should review.

Aarti Pharmalabs's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Aarti Pharmalabs Notes Receivable Related Terms

Aarti Pharmalabs Notes Receivable Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Notes Receivable Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:AARTIPHARM
50GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aarti Pharmalabs and its competitors.
Is Aarti Pharmalabs' Notes Receivable too high?
Aarti Pharmalabs' current Notes Receivable is ₹0 Mil. Overall, Aarti Pharmalabs has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Notes Receivable compare to ZTS and UTHR?
Aarti Pharmalabs' Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aarti Pharmalabs and its competitors. Aarti Pharmalabs's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹641.17, compared to a current price of ₹701.70 — trading 9.4% above its estimated fair value. The current Notes Receivable is ₹0 Mil. Aarti Pharmalabs' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹701.70 is trading 9.4% above its estimated GF Value™ of ₹641.17. GuruFocus considers Aarti Pharmalabs to be Fairly Valued.

Key valuation signals for NSE:AARTIPHARM:

  • Notes Receivable: ₹0 Mil
  • GF Value™: ₹641.17 vs. price of ₹701.70 (9.4% above fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
50GF Score

Get the complete analysis for NSE:AARTIPHARM

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹701.70
Price
₹641.17
GF Value